FDA approves MRK’s Zepatier* with recommended RAV screening for GT1a patients: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm It is recommended that healthcare professionals screen genotype 1a-infected patients for certain viral genetic variations prior to starting treatment with Zepatier to determine dosage regimen and duration. This is a good outcome for GILD, ABBV, and ENTA insofar as it will relegate Zepatier to afterthought status for most GT1a patients, IMO. MRK has not yet disclosed the US list price for Zepatier (pronounced ZEP-ah-teer), but this should happen within the next few hours. *Combination of elbasvir and grazoprevir.